[The testing of the carcinogenicity of dispirotripiperazine derivatives by combined administration with sodium...

The cancerogenic activity of the dispirotripiperasinium derivatives prospidine and spirobromine was tested in concurrent use with sodium nitrite. The drugs were intragastrically administered once a week. It was combined with sodium nitrite, 35 mg/kg, to non-inbred rats of both sex during 24 months. A morphological study revealed no statistically significant reduction of latency and no increase in the incidence of tumors in laboratory animals. No cancerogenic effect of sodium nitrite was found.